Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

No Change To Swine Flu Treatment Routes In Wales
Wales, along with the other devolved nations, will not be part of the National Pandemic Flu Service (NPFS) when it is launched next week in England, Health Minister Edwina Hart said today.
generic viagra online
Children Denied Immunizations At Increased Risk Of Whooping Cough
Children of parents who refuse vaccines are 23 times more likely to get whooping cough compared to fully immunized children, according to a new study led by a vaccine research team at Kaiser Permanente Colorado"s Institute for Health Research.
News of the day
Dr. Reddy's Receives Approval For Three INDs And Announces Reorganization Of Its Drug Discovery Operations
Dr. Reddy"s announced that the first human subjects were successfully dosed in a phase I study with DRL 17822, a selective inhibitor of CETP, for the treatment of dyslipidemia, atherosclerosis and associated cardiovascular diseases. The compound shows potent elevation in HDL-C and reduction of atherosclerotic plaques in animals, and has a clean safety profile in preclinical studies. The two other IND"s are for the treatment of COPD and dyslipidemia.
Endocrinology

Daiichi Sankyo And MorphoSys Expand Collaboration With Two New Cancer-Related Antibody Programs

MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) announced the start of a further two oncology-focused therapeutic antibody programs within its collaboration with DAIICHI SANKYO COMPANY, LIMITED (TSE: 4568, hereinafter Daiichi Sankyo). By exercising two options available under the parties" existing agreement, Daiichi Sankyo has selected two new target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL technology. Daiichi Sankyo will carry out pre-clinical and clinical development and has worldwide marketing rights for all resulting products. MorphoSys receives exclusive license fees and stands to receive milestones and royalties for the therapeutic antibody programs, as per the terms of the companies" existing agreement. Further financial details were not disclosed. "The addition of these new oncology programs promises to strengthen still further our partnered antibody pipeline", commented Dr. Simon Moroney, CEO of MorphoSys. "We look forward to working with Daiichi Sankyo on the programs, and making progress towards our declared goal of establishing a broad therapeutic pipeline of HuCAL-based antibody drugs." The two companies have been engaged in joint application of MorphoSys"s advanced phage display and human antibody library technologies since March 2006. In March 2008, Daiichi Sankyo exercised its option to extend the contracting period until March 2011. Today, the collaboration encompasses four active therapeutic antibody programs. In May 2008, Daiichi Sankyo further strengthened its pipeline of novel targeted therapeutics in oncology by acquiring the German biotechnology company U3 Pharma AG. The cancer-related target molecules, which build the basis for the HuCAL-based programs, were part of U3 Pharma"s portfolio. Daiichi Sankyo and MorphoSys AG


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009